CN103933444A - Traditional Chinese medicine composition used for treating epilepsy - Google Patents
Traditional Chinese medicine composition used for treating epilepsy Download PDFInfo
- Publication number
- CN103933444A CN103933444A CN201410053268.1A CN201410053268A CN103933444A CN 103933444 A CN103933444 A CN 103933444A CN 201410053268 A CN201410053268 A CN 201410053268A CN 103933444 A CN103933444 A CN 103933444A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- herba
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition used for treating epilepsy. The traditional Chinese medicine composition comprises following ingredients, rhizoma acori graminei, uncaria rhynchophylla, herba epimedii, antelope horn, rhizoma atractylodis macrocephalae, radix paeoniae rubra, Chinese date, herba ephedra, radix bupleuri, rhizoma anemarrhenae, poria cocos, concretio silicea bambusae, liquorice, spina gleditsiae, caulis sargentodoxae, polygonum cuspidatum, rhizoma et radix notopterygii, lucid ganoderma, cortex moutan, radix liriopes, radix campanumoeae, American ginseng, myrrh, loranthus parasiticus, rhizoma kaempferiae, pericarpium citri reticulatae, morinda officinalis, cymbopogon distans, and great burdock fruit. Curative effect of the traditional Chinese medicine composition is excellent; no obvious adverse drug reaction, or toxic and side effect is caused; the traditional Chinese medicine composition is capable of realizing comprehensive improvement of patient health states, and improving living quality of patients.
Description
Technical field
The present invention relates to Chinese medicine technical field, relate in particular to a kind of Chinese medicine composition that is used for the treatment of epilepsy.
Background technology
Epilepsy is department of neurology commonly encountered diseases, and according to epidemiologic data, the sickness rate of epilepsy in crowd is about 50～70/ (100,000 years), approximately has every year 65～700,000 new epileptic patients by Ci Shuaize China, and the total epileptic patient in the whole nation exceedes 6,000,000.2005 international epilepsy alliance (ILAE) epilepsy (epilepsy) is defined as: epilepsy is a kind of brain disorder, is characterized in having producing repeatedly the persistency tendency of epilepsy and having neural biological, cognitive, psychology and disease of brain that social multiple consequence is feature.And epilepsy really rule require to have epilepsy at least one time.
This disease onset is many at child and adolescence, is having a strong impact on patient's physical and mental health.It faces numb feature: when outbreak, hold down suddenly, dusk is not known people, slobbering, the eyes turning upwards, tic of the limbs, or mouthful in as make pig baa, while moving, revive, wake up after as ordinary person.
Approximately there is at present 80% patient can control outbreak through western medicine, but still have 20% patient to occur " refractory " phenomenon.Because primary disease often needs long-term treatment, there is more side effect in chemical synthetic drug, had a strong impact on patient's life quality, thus find the epilepsy Chinese medicine of highly effective and safe be clinical in the urgent need to.
Therefore, seek that toxic and side effects is little, the auxiliary epilepsy medicine of stable curative effect, in the hope of reducing the toxic and side effects of main flow epilepsy medicine, be the direction of epilepsy therapy research always.In recent years, along with medical science and pharmacological progress, theory of Chinese medical science has obtained the understanding of science as the accumulation of China's medical science experience in several thousand, and the experience of Chinese medicine aspect epilepsy therapy and effect also obtain the approval of research worker.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of Chinese medicine composition that is used for the treatment of epilepsy, and its good effect does not have obvious adverse effect and toxic and side effects, and patient's health status is improved comprehensively, thereby improves patient's quality of life.
For solving the problems of the technologies described above, the invention provides a kind of Chinese medicine composition that is used for the treatment of epilepsy, its crude drug comprises Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, the Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Rubra, Fructus Jujubae, Herba Ephedrae, Radix Bupleuri, the Rhizoma Anemarrhenae, Poria, Concretio Silicea Bambusae, Radix Glycyrrhizae, Spina Gleditsiae, Caulis Sargentodoxae, Rhizoma Polygoni Cuspidati, Rhizoma Et Radix Notopterygii, Ganoderma, Cortex Moutan, Radix Liriopes, Radix Campanumoeae, Radix Panacis Quinquefolii, Myrrha, Herba Taxilli, Rhizoma Kaempferiae, Pericarpium Citri Reticulatae, Radix Morindae Officinalis, Herba Cymbopogonis and Fructus Arctii.
Wherein, in described Chinese medicine composition, the weight of each crude drug is respectively Rhizoma Acori Graminei 25g～35g, Ramulus Uncariae Cum Uncis 35g～45g, Herba Epimedii 20g～30g, Cornu Saigae Tataricae 30g～40g, Rhizoma Atractylodis Macrocephalae 35g～45g, Radix Paeoniae Rubra 25g～35g, Fructus Jujubae 30g～40g, Herba Ephedrae 15g～25g, Radix Bupleuri 25g～35g, Rhizoma Anemarrhenae 30g～40g, Poria 20g～30g, Concretio Silicea Bambusae 35g～45g, Radix Glycyrrhizae 20g～30g, Spina Gleditsiae 15g～25g, Caulis Sargentodoxae 25g～35g, Rhizoma Polygoni Cuspidati 35g～45g, Rhizoma Et Radix Notopterygii 25g～35g, Ganoderma 20g～30g, Cortex Moutan 25g～35g, Radix Liriopes 30g～40g, Radix Campanumoeae 25g～35g, Radix Panacis Quinquefolii 35g～45g, Myrrha 25g～35g, Herba Taxilli 25g～35g, Rhizoma Kaempferiae 20g～30g, Pericarpium Citri Reticulatae 20g～30g, Radix Morindae Officinalis 25g～35g, Herba Cymbopogonis 15g～25g and Fructus Arctii 30g～40g.
Wherein, in described Chinese medicine composition, the weight of each crude drug is respectively Rhizoma Acori Graminei 30g～35g, Ramulus Uncariae Cum Uncis 40g～45g, Herba Epimedii 25g～30g, Cornu Saigae Tataricae 35g～40g, Rhizoma Atractylodis Macrocephalae 40g～45g, Radix Paeoniae Rubra 30g～35g, Fructus Jujubae 35g～40g, Herba Ephedrae 20g～25g, Radix Bupleuri 30g～35g, Rhizoma Anemarrhenae 35g～40g, Poria 25g～30g, Concretio Silicea Bambusae 40g～45g, Radix Glycyrrhizae 25g～30g, Spina Gleditsiae 15g～20g, Caulis Sargentodoxae 25g～30g, Rhizoma Polygoni Cuspidati 35g～40g, Rhizoma Et Radix Notopterygii 25g～30g, Ganoderma 20g～25g, Cortex Moutan 25g～30g, Radix Liriopes 30g～35g, Radix Campanumoeae 25g～30g, Radix Panacis Quinquefolii 35g～40g, Myrrha 25g～30g, Herba Taxilli 25g～30g, Rhizoma Kaempferiae 20g～25g, Pericarpium Citri Reticulatae 20g～25g, Radix Morindae Officinalis 25g～30g, Herba Cymbopogonis 15g～20g and Fructus Arctii 30g～35g.
Wherein, in described Chinese medicine composition, the weight of each crude drug is respectively Rhizoma Acori Graminei 30g, Ramulus Uncariae Cum Uncis 40g, Herba Epimedii 25g, Cornu Saigae Tataricae 35g, Rhizoma Atractylodis Macrocephalae 40g, Radix Paeoniae Rubra 30g, Fructus Jujubae 35g, Herba Ephedrae 20g, Radix Bupleuri 30g, Rhizoma Anemarrhenae 35g, Poria 25g, Concretio Silicea Bambusae 40g, Radix Glycyrrhizae 25g, Spina Gleditsiae 20g, Caulis Sargentodoxae 30g, Rhizoma Polygoni Cuspidati 40g, Rhizoma Et Radix Notopterygii 30g, Ganoderma 25g, Cortex Moutan 30g, Radix Liriopes 35g, Radix Campanumoeae 30g, Radix Panacis Quinquefolii 40g, Myrrha 30g, Herba Taxilli 30g, Rhizoma Kaempferiae 25g, Pericarpium Citri Reticulatae 25g, Radix Morindae Officinalis 30g, Herba Cymbopogonis 20g and Fructus Arctii 35g.
Wherein, described Chinese medicine composition can be prepared into capsule and granule.
The present invention also provides the preparation method of above-mentioned Chinese medicine composition, when when the dosage form of the Chinese medicine composition of preparation is capsule, be specially:
The first step, pulverizes Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, Herba Ephedrae, Radix Bupleuri, Concretio Silicea Bambusae, Spina Gleditsiae, Rhizoma Et Radix Notopterygii, Radix Liriopes, Radix Campanumoeae, Herba Taxilli, Rhizoma Kaempferiae, Herba Cymbopogonis and Fructus Arctii respectively, is placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use;
Second step, pulverizes crude drug component under She respectively, and the medicinal residues that obtain with the first step are mixed together evenly, obtain mixture, every 100g mixture adds the water of 300g, and heating decocts 3 hours, decoction liquor is filtered, and filtering residue decocts with water 2 hours again, and every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, be ground into powder and mix homogeneously with the cyclodextrin clathrate that the first step obtains, obtain mix products;
The 3rd step, the final mix products that second step is obtained is mixed homogeneously with starch, the amount of starch that every 100g mix products adds is 100g, adds determining alcohol and be 25% alcohol granulation, and the quality of the ethanol adding is equivalent to 0.1～0.2 times of mixture quality of mix products and starch, by particle drying, add magnesium stearate, the weight of magnesium stearate is equivalent to 0.01～0.02 times of mixture quality of mix products and starch, mix homogeneously, pack into in capsule, obtain capsule.
The present invention also provides the preparation method of above-mentioned Chinese medicine composition, when when the dosage form of the Chinese medicine composition of preparation is granule, be specially:
The first step, pulverizes Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, Herba Ephedrae, Radix Bupleuri, Concretio Silicea Bambusae, Spina Gleditsiae, Rhizoma Et Radix Notopterygii, Radix Liriopes, Radix Campanumoeae, Herba Taxilli, Rhizoma Kaempferiae, Herba Cymbopogonis and Fructus Arctii respectively, is placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use;
Second step, pulverizes crude drug component under She respectively, and the medicinal residues that obtain with the first step are mixed together evenly, obtain mixture, every 100g mixture adds the water of 300g, and heating decocts 3 hours, decoction liquor is filtered, and filtering residue decocts with water 2 hours again, and every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, be ground into powder and mix homogeneously with the cyclodextrin clathrate that the first step obtains, obtain mix products;
The 3rd step, every 100g mix products, adds soluble starch 200g, dextrin 200g, steviosin 3g, makes sugar-free granule, and dry, splitting takes up, every bag of 10g.
The present invention also provides a kind of Chinese medicinal composition granules that is used for the treatment of epilepsy, and its crude drug comprises Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, the Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Rubra, Fructus Jujubae, Herba Ephedrae, Radix Bupleuri, the Rhizoma Anemarrhenae, Poria, Concretio Silicea Bambusae, Radix Glycyrrhizae, Spina Gleditsiae, Caulis Sargentodoxae, Rhizoma Polygoni Cuspidati, Rhizoma Et Radix Notopterygii, Ganoderma, Cortex Moutan, Radix Liriopes, Radix Campanumoeae, Radix Panacis Quinquefolii, Myrrha, Herba Taxilli, Rhizoma Kaempferiae, Pericarpium Citri Reticulatae, Radix Morindae Officinalis, Herba Cymbopogonis and Fructus Arctii.
The present invention also provides a kind of Chinese medicinal composition capsules agent that is used for the treatment of epilepsy, and its crude drug comprises Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, the Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Rubra, Fructus Jujubae, Herba Ephedrae, Radix Bupleuri, the Rhizoma Anemarrhenae, Poria, Concretio Silicea Bambusae, Radix Glycyrrhizae, Spina Gleditsiae, Caulis Sargentodoxae, Rhizoma Polygoni Cuspidati, Rhizoma Et Radix Notopterygii, Ganoderma, Cortex Moutan, Radix Liriopes, Radix Campanumoeae, Radix Panacis Quinquefolii, Myrrha, Herba Taxilli, Rhizoma Kaempferiae, Pericarpium Citri Reticulatae, Radix Morindae Officinalis, Herba Cymbopogonis and Fructus Arctii.
Beneficial effect of the present invention:
Chinese medicine composition provided by the invention, having good effect aspect treatment epilepsy, does not have obvious adverse effect and toxic and side effects, patient's health status is improved comprehensively, thereby improved patient's quality of life.
Detailed description of the invention
Motherland's medical science, to the etiologic etiological understanding of epilepsy, is composed deficiency by examining in epilepsy syndrome is many, congenital weakness, and fear impairing kidney, or tumbling down shock, blood stagnant in cerebral venation syndrome or unhygienic diet, insect poison is invaded, or injures taste, the turbid interior life of expectorant.Diseases caused by exogenous pathogenic factor six climate exopathogens whenever, ailment said due to cold or exposure is done, or the liver failing to maintain the normal flow of QI, mechanism of qi is contrary disorderly, sun rises pneumatic, touches the retained phlegm superinverse of taking advantage of a favourable situation, hoodwink clearly key and cause epilepsy, thus epilepsy syndrome and liver spleen kidney three dirty relations the closest.Change of pathogenesis, with wind, expectorant, frightened, the stasis of blood is relevant, haunts with expectorant heresy the most important especially.
The traditional Chinese medical science thinks, wind, fire, expectorant, the stasis of blood, void are the main pathogenesis of primary disease, and therefore, many starting with from these aspects of clinical treatment determined the method for its treatments.Epilepsy invasion, especially taking " wind ", " expectorant " as wanting.Therefore eliminating phlegm relieves dizziness, high fever, infantile convulsions, epilepsy, etc., has one's ideas straightened out, analgesic therapy is the common method for the treatment of primary disease.Epilepsy belongs to mind illness, and intimately flourishing is often its main risk factor.Pathogenic fire on the one hand refining is endured body fluid, leads to heat-phlegm; In touching on the other hand, latent phlegm is turbid, makes expectorant with fire liter, and pericardium is covered in resistance, can make epilepsy.
In treatment, outbreak vital QI resisting pathogen of intermission, internal organs are manufactured, and wind-phlegm is flat temporarily, but the deficiency of vital energy, wind, expectorant, the tired cause of disease still exist, and forms deficiency in origin and excess in superficiality, and deficiency and excess is held concurrently mutually.According to TCM Syndrome Type typing standard, in " wind-phlegm is held under the arm in the stasis of blood, phlegm-fire and closed, caused by liver and kidney deficiency, deficiency-weakness of spleen-QI " four types, taking deficiency-weakness of spleen-QI card as many, have the existence of the excess pathogen such as wind, expectorant, the stasis of blood concurrently, void is it, takes stage of attack with the outbreak intermission and controls, taking the intermission as main, stress strengthening vital QI to eliminate pathogenic factors, use and adjust important department and battalion to defend method, make negative and positive mechanism of qi reach new balance.And set about from liver spleen two is dirty, be main legislation for the deficiency of vital energy and wind-phlegm two aspects of most critical in its basic pathogenesis.Prescription is to adjust important department and Ying Wei, and invigorating the spleen and benefiting QI, relieves dizziness, high fever, infantile convulsions, epilepsy, etc. and reduce phlegm, and the relieving convulsion of invigorating blood circulation is in a stove, and Cause & Symptom Solution, stresses to effect a permanent cure.Chinese medicine composition provided by the invention has the important department of tune and Ying Wei, replenishing QI to invigorate the spleen are main, and cooperation relieves dizziness, high fever, infantile convulsions, epilepsy, etc., Circulation Resolving Phlegm, and assistant is treated epilepsy with activating blood and removing stasis Method.
Based on this, the invention provides a kind of Chinese medicine composition that is used for the treatment of epilepsy, its crude drug comprises Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, the Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Rubra, Fructus Jujubae, Herba Ephedrae, Radix Bupleuri, the Rhizoma Anemarrhenae, Poria, Concretio Silicea Bambusae, Radix Glycyrrhizae, Spina Gleditsiae, Caulis Sargentodoxae, Rhizoma Polygoni Cuspidati, Rhizoma Et Radix Notopterygii, Ganoderma, Cortex Moutan, Radix Liriopes, Radix Campanumoeae, Radix Panacis Quinquefolii, Myrrha, Herba Taxilli, Rhizoma Kaempferiae, Pericarpium Citri Reticulatae, Radix Morindae Officinalis, Herba Cymbopogonis and Fructus Arctii.
Further, described Chinese medicine composition is only made up of above-mentioned raw materials medicine.
In described Chinese medicine composition, the weight of each crude drug is respectively Rhizoma Acori Graminei 25g～35g, Ramulus Uncariae Cum Uncis 35g～45g, Herba Epimedii 20g～30g, Cornu Saigae Tataricae 30g～40g, Rhizoma Atractylodis Macrocephalae 35g～45g, Radix Paeoniae Rubra 25g～35g, Fructus Jujubae 30g～40g, Herba Ephedrae 15g～25g, Radix Bupleuri 25g～35g, Rhizoma Anemarrhenae 30g～40g, Poria 20g～30g, Concretio Silicea Bambusae 35g～45g, Radix Glycyrrhizae 20g～30g, Spina Gleditsiae 15g～25g, Caulis Sargentodoxae 25g～35g, Rhizoma Polygoni Cuspidati 35g～45g, Rhizoma Et Radix Notopterygii 25g～35g, Ganoderma 20g～30g, Cortex Moutan 25g～35g, Radix Liriopes 30g～40g, Radix Campanumoeae 25g～35g, Radix Panacis Quinquefolii 35g～45g, Myrrha 25g～35g, Herba Taxilli 25g～35g, Rhizoma Kaempferiae 20g～30g, Pericarpium Citri Reticulatae 20g～30g, Radix Morindae Officinalis 25g～35g, Herba Cymbopogonis 15g～25g and Fructus Arctii 30g～40g.
Further preferably, in described Chinese medicine composition, the weight of each crude drug is respectively Rhizoma Acori Graminei 30g～35g, Ramulus Uncariae Cum Uncis 40g～45g, Herba Epimedii 25g～30g, Cornu Saigae Tataricae 35g～40g, Rhizoma Atractylodis Macrocephalae 40g～45g, Radix Paeoniae Rubra 30g～35g, Fructus Jujubae 35g～40g, Herba Ephedrae 20g～25g, Radix Bupleuri 30g～35g, Rhizoma Anemarrhenae 35g～40g, Poria 25g～30g, Concretio Silicea Bambusae 40g～45g, Radix Glycyrrhizae 25g～30g, Spina Gleditsiae 15g～20g, Caulis Sargentodoxae 25g～30g, Rhizoma Polygoni Cuspidati 35g～40g, Rhizoma Et Radix Notopterygii 25g～30g, Ganoderma 20g～25g, Cortex Moutan 25g～30g, Radix Liriopes 30g～35g, Radix Campanumoeae 25g～30g, Radix Panacis Quinquefolii 35g～40g, Myrrha 25g～30g, Herba Taxilli 25g～30g, Rhizoma Kaempferiae 20g～25g, Pericarpium Citri Reticulatae 20g～25g, Radix Morindae Officinalis 25g～30g, Herba Cymbopogonis 15g～20g and Fructus Arctii 30g～35g.
Most preferably, in described Chinese medicine composition, the weight of each crude drug is respectively Rhizoma Acori Graminei 30g, Ramulus Uncariae Cum Uncis 40g, Herba Epimedii 25g, Cornu Saigae Tataricae 35g, Rhizoma Atractylodis Macrocephalae 40g, Radix Paeoniae Rubra 30g, Fructus Jujubae 35g, Herba Ephedrae 20g, Radix Bupleuri 30g, Rhizoma Anemarrhenae 35g, Poria 25g, Concretio Silicea Bambusae 40g, Radix Glycyrrhizae 25g, Spina Gleditsiae 20g, Caulis Sargentodoxae 30g, Rhizoma Polygoni Cuspidati 40g, Rhizoma Et Radix Notopterygii 30g, Ganoderma 25g, Cortex Moutan 30g, Radix Liriopes 35g, Radix Campanumoeae 30g, Radix Panacis Quinquefolii 40g, Myrrha 30g, Herba Taxilli 30g, Rhizoma Kaempferiae 25g, Pericarpium Citri Reticulatae 25g, Radix Morindae Officinalis 30g, Herba Cymbopogonis 20g and Fructus Arctii 35g.
Chinese medicine composition provided by the invention can be prepared into capsule and granule.
The present invention also provides the preparation method of above-mentioned Chinese medicine composition, when when the dosage form of the Chinese medicine composition of preparation is capsule, be specially:
The first step, pulverizes Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, Herba Ephedrae, Radix Bupleuri, Concretio Silicea Bambusae, Spina Gleditsiae, Rhizoma Et Radix Notopterygii, Radix Liriopes, Radix Campanumoeae, Herba Taxilli, Rhizoma Kaempferiae, Herba Cymbopogonis and Fructus Arctii respectively, is placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use;
Second step, pulverizes crude drug component under She respectively, and the medicinal residues that obtain with the first step are mixed together evenly, obtain mixture, every 100g mixture adds the water of 300g, and heating decocts 3 hours, decoction liquor is filtered, and filtering residue decocts with water 2 hours again, and every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, be ground into powder and mix homogeneously with the cyclodextrin clathrate that the first step obtains, obtain mix products;
The 3rd step, the final mix products that second step is obtained is mixed homogeneously with starch, the amount of starch that every 100g mix products adds is 100g, adds determining alcohol and be 25% alcohol granulation, and the quality of the ethanol adding is equivalent to 0.1～0.2 times of mixture quality of mix products and starch, by particle drying, add magnesium stearate, the weight of magnesium stearate is equivalent to 0.01～0.02 times of mixture quality of mix products and starch, mix homogeneously, pack into in capsule, obtain capsule.
The present invention also provides the preparation method of above-mentioned Chinese medicine composition, when when the dosage form of the Chinese medicine composition of preparation is granule, be specially:
The first step, pulverizes Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, Herba Ephedrae, Radix Bupleuri, Concretio Silicea Bambusae, Spina Gleditsiae, Rhizoma Et Radix Notopterygii, Radix Liriopes, Radix Campanumoeae, Herba Taxilli, Rhizoma Kaempferiae, Herba Cymbopogonis and Fructus Arctii respectively, is placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use;
Second step, pulverizes crude drug component under She respectively, and the medicinal residues that obtain with the first step are mixed together evenly, obtain mixture, every 100g mixture adds the water of 300g, and heating decocts 3 hours, decoction liquor is filtered, and filtering residue decocts with water 2 hours again, and every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, be ground into powder and mix homogeneously with the cyclodextrin clathrate that the first step obtains, obtain mix products;
The 3rd step, every 100g mix products, adds soluble starch 200g, dextrin 200g, steviosin 3g, makes sugar-free granule, and dry, splitting takes up, every bag of 10g.
Below adopt embodiment to describe embodiments of the present invention in detail, to the present invention, how application technology means solve technical problem whereby, and the implementation procedure of reaching technique effect can fully understand and implement according to this.
Embodiment 1 capsule 1
Ramulus Uncariae Cum Uncis 40g, Herba Epimedii 25g, Cornu Saigae Tataricae 35g, Herba Ephedrae 20g, Radix Bupleuri 30g, Concretio Silicea Bambusae 40g, Spina Gleditsiae 20g, Rhizoma Et Radix Notopterygii 30g, Radix Liriopes 35g, Radix Campanumoeae 30g, Herba Taxilli 30g, Rhizoma Kaempferiae 25g, Herba Cymbopogonis 20g and Fructus Arctii 35g are pulverized respectively, be placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use, by Rhizoma Acori Graminei 30g, Rhizoma Atractylodis Macrocephalae 40g, Radix Paeoniae Rubra 30g, Fructus Jujubae 35g, Rhizoma Anemarrhenae 35g, Poria 25g, Radix Glycyrrhizae 25g, Caulis Sargentodoxae 30g, Rhizoma Polygoni Cuspidati 40g, Ganoderma 25g, Cortex Moutan 30g, Radix Panacis Quinquefolii 40g, Myrrha 30g, Pericarpium Citri Reticulatae 25g, Radix Morindae Officinalis 30g pulverizes respectively, be mixed together evenly with the medicinal residues that obtain above, obtain mixture, every 100g mixture adds the water of 300g, heating decocts 3 hours, decoction liquor is filtered, filtering residue decocts with water 2 hours again, every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, being ground into powder mixs homogeneously with the cyclodextrin clathrate obtaining above, obtain mix products, the final mix products obtaining is mixed homogeneously with starch, the amount of starch that every 100g mix products adds is 100g, add determining alcohol and be 25% alcohol granulation, the quality of the ethanol adding is equivalent to 0.1 times of mixture quality of mix products and starch, by particle drying, add magnesium stearate, the weight of magnesium stearate is equivalent to 0.01 times of mixture quality of mix products and starch, mix homogeneously, pack into in capsule, obtain capsule.
Embodiment 2 capsules 2
Ramulus Uncariae Cum Uncis 45g, Herba Epimedii 30g, Cornu Saigae Tataricae 40g, Herba Ephedrae 25g, Radix Bupleuri 35g, Concretio Silicea Bambusae 45g, Spina Gleditsiae 20g, Rhizoma Et Radix Notopterygii 30g, Radix Liriopes 35g, Radix Campanumoeae 30g, Herba Taxilli 30g, Rhizoma Kaempferiae 25g, Herba Cymbopogonis 20g and Fructus Arctii 35g are pulverized respectively, be placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use, by Rhizoma Acori Graminei 35g, Rhizoma Atractylodis Macrocephalae 45g, Radix Paeoniae Rubra 35g, Fructus Jujubae 40g, Rhizoma Anemarrhenae 40g, Poria 30g, Radix Glycyrrhizae 30g, Caulis Sargentodoxae 30g, Rhizoma Polygoni Cuspidati 40g, Ganoderma 25g, Cortex Moutan 30g, Radix Panacis Quinquefolii 40g, Myrrha 30g, Pericarpium Citri Reticulatae 25g, Radix Morindae Officinalis 30g pulverizes respectively, be mixed together evenly with the medicinal residues that obtain above, obtain mixture, every 100g mixture adds the water of 300g, heating decocts 3 hours, decoction liquor is filtered, filtering residue decocts with water 2 hours again, every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, being ground into powder mixs homogeneously with the cyclodextrin clathrate obtaining above, obtain mix products, the final mix products obtaining is mixed homogeneously with starch, the amount of starch that every 100g mix products adds is 100g, add determining alcohol and be 25% alcohol granulation, the quality of the ethanol adding is equivalent to 0.1 times of mixture quality of mix products and starch, by particle drying, add magnesium stearate, the weight of magnesium stearate is equivalent to 0.01 times of mixture quality of mix products and starch, mix homogeneously, pack into in capsule, obtain capsule.
Embodiment 3 capsules 3
Ramulus Uncariae Cum Uncis 40g, Herba Epimedii 25g, Cornu Saigae Tataricae 35g, Herba Ephedrae 20g, Radix Bupleuri 30g, Concretio Silicea Bambusae 40g, Spina Gleditsiae 15g, Rhizoma Et Radix Notopterygii 25g, Radix Liriopes 30g, Radix Campanumoeae 25g, Herba Taxilli 25g, Rhizoma Kaempferiae 20g, Herba Cymbopogonis 15g and Fructus Arctii 30g are pulverized respectively, be placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use, by Rhizoma Acori Graminei 30g, Rhizoma Atractylodis Macrocephalae 40g, Radix Paeoniae Rubra 30g, Fructus Jujubae 35g, Rhizoma Anemarrhenae 35g, Poria 25g, Radix Glycyrrhizae 25g, Caulis Sargentodoxae 25g, Rhizoma Polygoni Cuspidati 35g, Ganoderma 20g, Cortex Moutan 25g, Radix Panacis Quinquefolii 35g, Myrrha 25g, Pericarpium Citri Reticulatae 20g, Radix Morindae Officinalis 25g pulverizes respectively, be mixed together evenly with the medicinal residues that obtain above, obtain mixture, every 100g mixture adds the water of 300g, heating decocts 3 hours, decoction liquor is filtered, filtering residue decocts with water 2 hours again, every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, being ground into powder mixs homogeneously with the cyclodextrin clathrate obtaining above, obtain mix products, the final mix products obtaining is mixed homogeneously with starch, the amount of starch that every 100g mix products adds is 100g, add determining alcohol and be 25% alcohol granulation, the quality of the ethanol adding is equivalent to 0.1 times of mixture quality of mix products and starch, by particle drying, add magnesium stearate, the weight of magnesium stearate is equivalent to 0.01 times of mixture quality of mix products and starch, mix homogeneously, pack into in capsule, obtain capsule.
Embodiment 4 granules
Ramulus Uncariae Cum Uncis 40g, Herba Epimedii 25g, Cornu Saigae Tataricae 35g, Herba Ephedrae 20g, Radix Bupleuri 30g, Concretio Silicea Bambusae 40g, Spina Gleditsiae 20g, Rhizoma Et Radix Notopterygii 30g, Radix Liriopes 35g, Radix Campanumoeae 30g, Herba Taxilli 30g, Rhizoma Kaempferiae 25g, Herba Cymbopogonis 20g and Fructus Arctii 35g are pulverized respectively, be placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use, by Rhizoma Acori Graminei 30g, Rhizoma Atractylodis Macrocephalae 40g, Radix Paeoniae Rubra 30g, Fructus Jujubae 35g, Rhizoma Anemarrhenae 35g, Poria 25g, Radix Glycyrrhizae 25g, Caulis Sargentodoxae 30g, Rhizoma Polygoni Cuspidati 40g, Ganoderma 25g, Cortex Moutan 30g, Radix Panacis Quinquefolii 40g, Myrrha 30g, Pericarpium Citri Reticulatae 25g, Radix Morindae Officinalis 30g pulverizes respectively, be mixed together evenly with the medicinal residues that obtain above, obtain mixture, every 100g mixture adds the water of 300g, heating decocts 3 hours, decoction liquor is filtered, filtering residue decocts with water 2 hours again, every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, being ground into powder mixs homogeneously with the cyclodextrin clathrate obtaining above, obtain mix products, every 100g mix products, add soluble starch 200g, dextrin 200g, steviosin 3g, make sugar-free granule, dry, splitting takes up, every bag of 10g.
Embodiment 5
Embodiment 4 toxicity tests
Acute toxicity testing
Require to carry out prerun according to acute toxicity test, find that tested medicine cannot measure LD
50.Therefore carry out maximum dosage-feeding test in a day.Get 40 of above-mentioned mices, fasting be can't help water after 12 hours, be divided at random administration group and water matched group by body weight, every group 20, administration group is given the medicinal liquid 0.4ml/10g of the crude drug amount 2.4g/ml concentration of the Chinese medicine granules of preparing containing embodiment 1, gavage one day 2 times, makes dosage in a day reach symphysis dose 192.0g/kg, and water matched group is to the water of equal volume.After each treated animal administration, 5, every box, normal raising, close observation, all Continuous Observations seven days, the toxic reaction that record may occur and death condition, after administration, mice outward appearance hair color light, behavioral activity is normal, occur without abnormal pathologic neural reflex, in seven days, well, other Novel presentation is seen at end in feed, and body weight change is no significant difference and none animal dead compared with water matched group, the main organs such as the perusal heart, liver, spleen, lung, kidney, without general pathology changes such as significantly hemorrhage, tissue degeneratiaon, necrosis.
Long term toxicity test
Experiment is established 2 groups altogether: Chinese drug-treated group of the present invention (dosage is respectively 51.6g crude drug in whole/kg) and blank group, to 9 week age rat within continuous 180 days, gavage, administration 90 days, 180 days and drug withdrawal are after 30 days, put to death respectively rat, check each treated animal hematological indices [erythrocyte (RBC), mean corpuscular volume (MCV) (MCV), hematid specific volume (HCT), platelet (PLT), mean platelet volume (MPV), leukocyte (WBC), hemoglobin (HGB), mean corpusular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) (MCHC), lymphocyte percentage (LPR), neutrophil percentage (GPR), intermediate value cell percentage (MPR), Erythrocyte hemoglobin distribution width (RDWR), Erythrocyte hemoglobin distribution width number (RDWA), Reticulocyte percentage (RET), blood zymogen time (PT) agglutinates], blood biochemical is learned index [glutamate pyruvate transaminase (ALT), total protein (TP), albumin (ALB), total bilirubin (TBIL), glutamic oxaloacetic transaminase, GOT (AST), creatine kinase (CK), creatinine (CREA), blood urea nitrogen (BUN), blood glucose (GLU), T-CHOL (CHOL), triglyceride (TG), glutamine aminotransferase (GGT), alkali phosphatase (ALP), serum potassium ion (K
+), serum sodium ion (Na
+), serum chloride ion (Cl
-)].All animal hearts, liver, spleen, lung, kidney, brain, uterus, ovary, thymus, adrenal gland are carried out to perusal, and the calculating organ index of weighing; Simultaneously to blank group and the Chinese drug-treated group animal heart, liver, spleen, lung, kidney, brain (brain, cerebellum, brain stem), hypophysis, optic nerve, sciatic nerve, spinal cord (cervical part of esophagus, breast section, waist section), uterus, ovary, mammary gland, thyroid, thymus, pancreas, adrenal gland, salivary gland (submaxillary gland), esophagus, Stomach duodenum, return, colon, bladder, lymph node (submandibular lymph nodes, mesenteric lymph node), trachea, aorta carry out pathomorphology inspection.
Result shows: each administration treated animal is in the different dosing cycle, above index and matched group comparison, and all without anomaly, hematology and biochemical indexes are all in range of normal value.
Result shows that it is safe that Chinese medicine composition long-term, high-dose of the present invention uses.
Embodiment 6 clinical datas
Physical data
Observe case 332 examples, be divided at random two groups.Treatment group 180 examples, male 112 examples, female's 68 examples; 6～59 years old age, average 28.05 years old; The course of disease 0.25～30 year, average 8.2 years.Seizure types: simple partial seizure 26 examples, complex partial seizures 36 examples, comprehensive petit mal 28 examples, tetanic, Myoclonic seizures 78 examples, other Class1 2 examples; Seizure frequency 18 times/day～1 time/90 days, average 1 time/16.5 days; Abnormal (positive) 156 examples of electroencephalogram (EEG).Matched group 152 examples, male 94 examples, female's 58 examples; 7～56 years old age, average 25.15 years old; The course of disease 0.3～32 year, average 7.8 years.Seizure types: pure partial seizure 22 examples, complex partial 30 examples of showing effect, comprehensive petit mal 24 examples, tetanic, Myoclonic seizures 66 examples, other Class1 0 example; Seizure frequency 10 times/day～1 time/120 days, average 1 time/18 days; Positive 67 examples of electroencephalogram.All cases check all without obvious morphological change through head CT or MRI.Two groups of cases are analyzed there was no significant difference (P > 0.05) at aspects such as sex, age, the course of disease, clinical manifestations through Ridit, have comparability.
Therapeutic Method
Matched group gives respectively carbamazepine (partial seizures), clonazepam (Generalized seizure and other type) common dose oral medication according to seizure types, as far as possible inactive other antiepileptic of all cases, if aggravation after changing dressings, does not change original medication.Treatment group adopts the capsule prepared of the embodiment of the present invention 1, every 0.5g, one time 3, every day 3 times, add simultaneously and use the western medicine identical with matched group.Per season of all cases check EEG1 time, two groups of cases are all treated and after 18 months, are carried out clinical efficacy and toxicity relative analysis.Then to two groups clinical near more and the EEG person of turning out cloudy drug withdrawal follow up a case by regular visits to 6 months, observe its clinical recurrence situation.
Criterion of therapeutical effect
With reference to disease of tcm Standardization of diagnosis and curative effect.Near: with outbreak intermittent time comparison before treatment, to extend 1 year and do not send out above author; Take a turn for the better: when outbreak, symptom alleviates before treating, and the intermission obviously extends; Do not heal: the frequent or symptom of outbreak increases the weight of.
Efficacy analysis
Two groups of clinical effectiveness comparisons, the results are shown in Table 1.
Table 1 liang group clinical effectiveness comparison
| Group | Number of cases | Near | Take a turn for the better | Do not heal | Total effective rate |
| Treatment group | 180 | 93 | 78 | 9 | 95.00％ |
| Matched group | 152 | 31 | 65 | 56 | 63.16％ |
As can be known from Table 1, treatment group closely more and total effective rate all apparently higher than matched group.
The comparison of two groups of EEG improvement rates, the results are shown in Table 2.
Table 2 liang group EEG improvement rate comparison
| Group | Positive | Turn out cloudy | Take a turn for the better | Without improving | Total improvement rate |
| Treatment group | 149 | 46 | 64 | 39 | 73.83％ |
| Matched group | 137 | 15 | 53 | 69 | 49.64％ |
Treatment group EEG negative conversion rate and total improvement rate are all better than matched group.
All above-mentioned these intellectual properties of primary enforcement, do not set restriction this new product of other forms of enforcement and/or new method.Those skilled in the art will utilize this important information, and foregoing amendment, to realize similar implementation status.But all modifications or transformation belong to the right of reservation based on new product of the present invention.
The above, be only preferred embodiment of the present invention, is not the restriction of the present invention being made to other form, and any those skilled in the art may utilize the technology contents of above-mentioned announcement to be changed or be modified as the equivalent embodiment of equivalent variations.But every technical solution of the present invention content that do not depart from, any simple modification, equivalent variations and the remodeling above embodiment done according to technical spirit of the present invention, still belong to the protection domain of technical solution of the present invention.
Claims (9)
1. a Chinese medicine composition that is used for the treatment of epilepsy, is characterized in that: crude drug comprises Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, the Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Rubra, Fructus Jujubae, Herba Ephedrae, Radix Bupleuri, the Rhizoma Anemarrhenae, Poria, Concretio Silicea Bambusae, Radix Glycyrrhizae, Spina Gleditsiae, Caulis Sargentodoxae, Rhizoma Polygoni Cuspidati, Rhizoma Et Radix Notopterygii, Ganoderma, Cortex Moutan, Radix Liriopes, Radix Campanumoeae, Radix Panacis Quinquefolii, Myrrha, Herba Taxilli, Rhizoma Kaempferiae, Pericarpium Citri Reticulatae, Radix Morindae Officinalis, Herba Cymbopogonis and Fructus Arctii.
2. Chinese medicine composition as claimed in claim 1, it is characterized in that: the weight of each crude drug is respectively Rhizoma Acori Graminei 25g～35g, Ramulus Uncariae Cum Uncis 35g～45g, Herba Epimedii 20g～30g, Cornu Saigae Tataricae 30g～40g, Rhizoma Atractylodis Macrocephalae 35g～45g, Radix Paeoniae Rubra 25g～35g, Fructus Jujubae 30g～40g, Herba Ephedrae 15g～25g, Radix Bupleuri 25g～35g, Rhizoma Anemarrhenae 30g～40g, Poria 20g～30g, Concretio Silicea Bambusae 35g～45g, Radix Glycyrrhizae 20g～30g, Spina Gleditsiae 15g～25g, Caulis Sargentodoxae 25g～35g, Rhizoma Polygoni Cuspidati 35g～45g, Rhizoma Et Radix Notopterygii 25g～35g, Ganoderma 20g～30g, Cortex Moutan 25g～35g, Radix Liriopes 30g～40g, Radix Campanumoeae 25g～35g, Radix Panacis Quinquefolii 35g～45g, Myrrha 25g～35g, Herba Taxilli 25g～35g, Rhizoma Kaempferiae 20g～30g, Pericarpium Citri Reticulatae 20g～30g, Radix Morindae Officinalis 25g～35g, Herba Cymbopogonis 15g～25g and Fructus Arctii 30g～40g.
3. Chinese medicine composition as claimed in claim 1 or 2, it is characterized in that: the weight of each crude drug is respectively Rhizoma Acori Graminei 30g～35g, Ramulus Uncariae Cum Uncis 40g～45g, Herba Epimedii 25g～30g, Cornu Saigae Tataricae 35g～40g, Rhizoma Atractylodis Macrocephalae 40g～45g, Radix Paeoniae Rubra 30g～35g, Fructus Jujubae 35g～40g, Herba Ephedrae 20g～25g, Radix Bupleuri 30g～35g, Rhizoma Anemarrhenae 35g～40g, Poria 25g～30g, Concretio Silicea Bambusae 40g～45g, Radix Glycyrrhizae 25g～30g, Spina Gleditsiae 15g～20g, Caulis Sargentodoxae 25g～30g, Rhizoma Polygoni Cuspidati 35g～40g, Rhizoma Et Radix Notopterygii 25g～30g, Ganoderma 20g～25g, Cortex Moutan 25g～30g, Radix Liriopes 30g～35g, Radix Campanumoeae 25g～30g, Radix Panacis Quinquefolii 35g～40g, Myrrha 25g～30g, Herba Taxilli 25g～30g, Rhizoma Kaempferiae 20g～25g, Pericarpium Citri Reticulatae 20g～25g, Radix Morindae Officinalis 25g～30g, Herba Cymbopogonis 15g～20g and Fructus Arctii 30g～35g.
4. the Chinese medicine composition as described in claims 1 to 3, it is characterized in that: the weight of each crude drug is respectively Rhizoma Acori Graminei 30g, Ramulus Uncariae Cum Uncis 40g, Herba Epimedii 25g, Cornu Saigae Tataricae 35g, Rhizoma Atractylodis Macrocephalae 40g, Radix Paeoniae Rubra 30g, Fructus Jujubae 35g, Herba Ephedrae 20g, Radix Bupleuri 30g, Rhizoma Anemarrhenae 35g, Poria 25g, Concretio Silicea Bambusae 40g, Radix Glycyrrhizae 25g, Spina Gleditsiae 20g, Caulis Sargentodoxae 30g, Rhizoma Polygoni Cuspidati 40g, Rhizoma Et Radix Notopterygii 30g, Ganoderma 25g, Cortex Moutan 30g, Radix Liriopes 35g, Radix Campanumoeae 30g, Radix Panacis Quinquefolii 40g, Myrrha 30g, Herba Taxilli 30g, Rhizoma Kaempferiae 25g, Pericarpium Citri Reticulatae 25g, Radix Morindae Officinalis 30g, Herba Cymbopogonis 20g and Fructus Arctii 35g.
5. the Chinese medicine composition as described in claim 1 to 4, is characterized in that: described Chinese medicine composition can be prepared into capsule and granule.
6. the preparation method of Chinese medicine composition described in claim 1 to 5, is characterized in that: when when the dosage form of the Chinese medicine composition of preparation is capsule, be specially,
The first step, pulverizes Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, Herba Ephedrae, Radix Bupleuri, Concretio Silicea Bambusae, Spina Gleditsiae, Rhizoma Et Radix Notopterygii, Radix Liriopes, Radix Campanumoeae, Herba Taxilli, Rhizoma Kaempferiae, Herba Cymbopogonis and Fructus Arctii respectively, is placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use;
Second step, pulverizes crude drug component under She respectively, and the medicinal residues that obtain with the first step are mixed together evenly, obtain mixture, every 100g mixture adds the water of 300g, and heating decocts 3 hours, decoction liquor is filtered, and filtering residue decocts with water 2 hours again, and every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, be ground into powder and mix homogeneously with the cyclodextrin clathrate that the first step obtains, obtain mix products;
The 3rd step, the final mix products that second step is obtained is mixed homogeneously with starch, the amount of starch that every 100g mix products adds is 100g, adds determining alcohol and be 25% alcohol granulation, and the quality of the ethanol adding is equivalent to 0.1～0.2 times of mixture quality of mix products and starch, by particle drying, add magnesium stearate, the weight of magnesium stearate is equivalent to 0.01～0.02 times of mixture quality of mix products and starch, mix homogeneously, pack into in capsule, obtain capsule.
7. the preparation method of Chinese medicine composition described in claim 1 to 5, is characterized in that: when when the dosage form of the Chinese medicine composition of preparation is granule, be specially,
The first step, pulverizes Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, Herba Ephedrae, Radix Bupleuri, Concretio Silicea Bambusae, Spina Gleditsiae, Rhizoma Et Radix Notopterygii, Radix Liriopes, Radix Campanumoeae, Herba Taxilli, Rhizoma Kaempferiae, Herba Cymbopogonis and Fructus Arctii respectively, is placed in respectively supercritical CO
2in the extractor of device, extract, obtain extract, extract is mixed, add the cyclodextrin inclusion compound with respect to 4 times of quality of extract, obtain cyclodextrin clathrate, for subsequent use, pass through supercritical CO
2the medicinal residues of the crude drug extracting mix, for subsequent use;
Second step, pulverizes crude drug component under She respectively, and the medicinal residues that obtain with the first step are mixed together evenly, obtain mixture, every 100g mixture adds the water of 300g, and heating decocts 3 hours, decoction liquor is filtered, and filtering residue decocts with water 2 hours again, and every 100g filtering residue adds the water of 200g, decoction liquor is filtered, filtrate after twice filtration is mixed, concentrated except desolventizing, obtain and get dry extract, be ground into powder and mix homogeneously with the cyclodextrin clathrate that the first step obtains, obtain mix products;
The 3rd step, every 100g mix products, adds soluble starch 200g, dextrin 200g, steviosin 3g, makes sugar-free granule, and dry, splitting takes up, every bag of 10g.
8. a Chinese medicinal composition granules that is used for the treatment of epilepsy, is characterized in that: crude drug comprises Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, the Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Rubra, Fructus Jujubae, Herba Ephedrae, Radix Bupleuri, the Rhizoma Anemarrhenae, Poria, Concretio Silicea Bambusae, Radix Glycyrrhizae, Spina Gleditsiae, Caulis Sargentodoxae, Rhizoma Polygoni Cuspidati, Rhizoma Et Radix Notopterygii, Ganoderma, Cortex Moutan, Radix Liriopes, Radix Campanumoeae, Radix Panacis Quinquefolii, Myrrha, Herba Taxilli, Rhizoma Kaempferiae, Pericarpium Citri Reticulatae, Radix Morindae Officinalis, Herba Cymbopogonis and Fructus Arctii.
9. be used for the treatment of a Chinese medicinal composition capsules agent for epilepsy, it is characterized in that: crude drug comprises Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis, Herba Epimedii, Cornu Saigae Tataricae, the Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Rubra, Fructus Jujubae, Herba Ephedrae, Radix Bupleuri, the Rhizoma Anemarrhenae, Poria, Concretio Silicea Bambusae, Radix Glycyrrhizae, Spina Gleditsiae, Caulis Sargentodoxae, Rhizoma Polygoni Cuspidati, Rhizoma Et Radix Notopterygii, Ganoderma, Cortex Moutan, Radix Liriopes, Radix Campanumoeae, Radix Panacis Quinquefolii, Myrrha, Herba Taxilli, Rhizoma Kaempferiae, Pericarpium Citri Reticulatae, Radix Morindae Officinalis, Herba Cymbopogonis and Fructus Arctii.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410053268.1A CN103933444A (en) | 2014-02-17 | 2014-02-17 | Traditional Chinese medicine composition used for treating epilepsy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410053268.1A CN103933444A (en) | 2014-02-17 | 2014-02-17 | Traditional Chinese medicine composition used for treating epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103933444A true CN103933444A (en) | 2014-07-23 |
Family
ID=51181500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410053268.1A Pending CN103933444A (en) | 2014-02-17 | 2014-02-17 | Traditional Chinese medicine composition used for treating epilepsy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103933444A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106994A (en) * | 2009-12-28 | 2011-06-29 | 曹斌 | Treatment formula for epilepsies and manufacturing method thereof |
| CN102552713A (en) * | 2012-02-28 | 2012-07-11 | 卢卫平 | Medicine for treating epilepsy and preparation method thereof |
| CN103285093A (en) * | 2013-07-02 | 2013-09-11 | 李伟丽 | Traditional Chinese medicine composition for treating epilepsy |
-
2014
- 2014-02-17 CN CN201410053268.1A patent/CN103933444A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106994A (en) * | 2009-12-28 | 2011-06-29 | 曹斌 | Treatment formula for epilepsies and manufacturing method thereof |
| CN102552713A (en) * | 2012-02-28 | 2012-07-11 | 卢卫平 | Medicine for treating epilepsy and preparation method thereof |
| CN103285093A (en) * | 2013-07-02 | 2013-09-11 | 李伟丽 | Traditional Chinese medicine composition for treating epilepsy |
Non-Patent Citations (2)
| Title |
|---|
| 朱欧鸰: "《单纯中药治疗癫痫病的研究进展》", 《世界中西医结合杂志》 * |
| 林玉霖: "宁痫中药胶囊治疗癫痫180例疗效观察", 《福建医药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101444611A (en) | Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof | |
| CN101879278B (en) | Medicine composition with hyperglycemic function, and preparation method and application thereof | |
| CN104338078A (en) | Pharmaceutical composition for treating intrahepatic cholestasis in gestation period | |
| CN104001072A (en) | Pharmaceutical composition for prevention and treatment of diabetes | |
| CN102441063B (en) | Pharmaceutical composition for treating thrombocytopenia, and preparation method and application thereof | |
| CN101829291B (en) | Traditional Chinese medicine preparation for treating rheumatism and preparation method thereof | |
| CN101380359B (en) | Bone-building capsules and preparation method thereof | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN103933444A (en) | Traditional Chinese medicine composition used for treating epilepsy | |
| CN105250440B (en) | A kind of lenitive Chinese medicine composition and its application | |
| CN102125671B (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN102106993A (en) | Chinese medicinal composition for treating fatty liver and preparation method thereof | |
| CN101485672B (en) | Application of hylotelephin in preparing medicament for treating human HBeAg-positive chronic hepatitis B | |
| CN105770661B (en) | Preparation method of Zukamu granules | |
| CN104288231A (en) | Medicine for treating refractory epilepsy | |
| CN104436049A (en) | Traditional Chinese medicine composition for treating heart disease | |
| CN110179947B (en) | Medicine for nourishing yin and soothing liver, preparation method and application thereof | |
| CN102872332A (en) | Bao yaowang medicinal and edible Chinese medicinal herb composition for treating blood diseases and preparation method and application thereof | |
| CN101979084B (en) | Chinese medicinal composition for warming kidney and tonifying yang and preparation method thereof | |
| CN106511881B (en) | A Chinese medicinal composition for invigorating kidney and preventing miscarriage, and its preparation method | |
| Peter et al. | Cytoprotective effects of ethanolic extract of Vernonium amygdalina leaves on alloxan induced hepato-toxicity in albino wistar rats | |
| CN101912497B (en) | Medicament for treating bone fracture | |
| CN106924330A (en) | A kind of application of Aidi preparation in anti-MPM medicine is prepared | |
| CN105998629A (en) | Traditional Chinese medicine composition for treating syndrome of qi stagnation and blood stasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140723 |